TRAIL receptor signaling and therapeutics

Bibliography

• Wiley SR, Schooley K, Smolak PJ, Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82
   PubMed Web of Science ®Google Scholar
• Kuribayashi K, Krigsfeld G, Wang W, TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008;7:2034-8
   PubMed Web of Science ®Google Scholar
• Droin NM, Pinkoski MJ, Dejardin E, Green DR. Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol Cell Biol 2003;23:7638-47
   PubMed Web of Science ®Google Scholar
• Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 2004;23:3051-60
   PubMed Web of Science ®Google Scholar
• Ravi R, Bedi GC, Engstrom LW, Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001;3:409-16
   PubMed Web of Science ®Google Scholar
• Xu J, Zhou JY, Wei WZ, Sp1-mediated TRAIL induction in chemosensitization. Cancer Res 2008;68:6718-26
   PubMed Web of Science ®Google Scholar
• Ueno S, Tatetsu H, Hata H, PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL. Oncogene 2009;28:4116-25
   PubMed Web of Science ®Google Scholar
• Kischkel FC, Lawrence DA, Chuntharapai A, Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-20
   PubMed Web of Science ®Google Scholar
• Chang DW, Xing Z, Pan Y, c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002;21(14):3704-14
   PubMed Web of Science ®Google Scholar
• Jin Z, Li Y, Pitti R, Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009;137:721-35
   PubMed Web of Science ®Google Scholar
• Waterhouse NJ, Ricci JE, Green DR. And all of a sudden it's over: mitochondrial outer-membrane permeabilization in apoptosis. Biochimie 2002;84:113-21
   PubMed Web of Science ®Google Scholar
• Shi Y. Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci 2004;13:1979-87
   PubMed Web of Science ®Google Scholar
• Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004;23:2797-808
   PubMed Web of Science ®Google Scholar
• Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005;280:15709-18
   PubMed Web of Science ®Google Scholar
• Baader E, Toloczko A, Fuchs U, Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res 2005;65:7888-95
   PubMed Web of Science ®Google Scholar
• Ehrhardt H, Fulda S, Schmid I, TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003;22:3842-52
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-75
   PubMed Web of Science ®Google Scholar
• Mills KR, Reginato M, Debnath J, Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci USA 2004;101:3438-43
   PubMed Web of Science ®Google Scholar
• Cretney E, Takeda K, Yagita H, Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002;168:1356-61
   PubMed Web of Science ®Google Scholar
• Takeda K, Hayakawa Y, Smyth MJ, Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 2001;7:94-100
   PubMed Web of Science ®Google Scholar
• Liu S, Yu Y, Zhang M, The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 2001;166:5407-15
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Takeda K, Hayakawa Y, Nature's TRAIL – on a path to cancer immunotherapy. Immunity 2003;18:1-6
   PubMed Web of Science ®Google Scholar
• Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005;17:180-6
   PubMed Web of Science ®Google Scholar
• Mace TA, Yamane N, Cheng J, The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis. Immunol Invest 2006;35:279-96
   PubMed Web of Science ®Google Scholar
• Kaelin WG Jr. The von hippel-lindau tumor suppressor protein: an update. Methods Enzymol 2007;435:371-83
   PubMed Web of Science ®Google Scholar
• Kim M, Park SY, Pai HS, Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res 2004;64:4078-81
   PubMed Web of Science ®Google Scholar
• Trauzold A, Siegmund D, Schniewind B, TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006;25:7434-9
   PubMed Web of Science ®Google Scholar
• Lub-de Hooge MN, de Vries EG, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:854-8
   PubMedGoogle Scholar
• Wandinger KP, Lunemann JD, Wengert O, TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003;361:2036-43
   PubMed Web of Science ®Google Scholar
• Diehl GE, Yue HH, Hsieh K, TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004;21:877-89
   PubMed Web of Science ®Google Scholar
• Pai SI, Wu GS, Ozoren N, Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998;58:3513-18
   PubMed Web of Science ®Google Scholar
• Wang S, El-Deiry WS. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res 2004;64(18):6666-72
   PubMed Web of Science ®Google Scholar
• Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008;118:111-23
   Google Scholar
• Finnberg N, Gruber JJ, Fei P, DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 2005;25:2000-13
   PubMed Web of Science ®Google Scholar
• Laguinge LM, Samara RN, Wang W, DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res 2008;68:909-17
   PubMed Web of Science ®Google Scholar
• Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008;27:6207-15
   PubMed Web of Science ®Google Scholar
• Grosse-Wilde A, Voloshanenko O, Bailey SL, TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008;118:100-10
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63
   PubMed Web of Science ®Google Scholar
• Lane D, Cartier A, L'Esperance S, Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol Oncol 2004;93:594-604
   PubMed Web of Science ®Google Scholar
• Li Y, Wang H, Wang Z, Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Cancer Res 2006;66:8520-8
   Google Scholar
• Garofalo M, Quintavalle C, Di Leva G, MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008;27:3845-55
   PubMed Web of Science ®Google Scholar
• Garofalo M, Di Leva G, Romano G, miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509
   PubMed Web of Science ®Google Scholar
• Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2000;60:4315-19
   PubMed Web of Science ®Google Scholar
• Eramo A, Pallini R, Lotti F, Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 2005;65:11469-77
   PubMed Web of Science ®Google Scholar
• Cummins JM, Kohli M, Rago C, X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 2004;64:3006-8
   PubMed Web of Science ®Google Scholar
• Ricci MS, Kim SH, Ogi K, Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80
   PubMed Web of Science ®Google Scholar
• Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15
   PubMed Web of Science ®Google Scholar
• Xiao C, Yang BF, Asadi N, Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002;277:25020-5
   PubMed Web of Science ®Google Scholar
• Koornstra JJ, Kleibeuker JH, van Geelen CM, Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003;200:327-35
   PubMed Web of Science ®Google Scholar
• Ricci MS, Jin Z, Dews M, Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004;24:8541-55
   PubMed Web of Science ®Google Scholar
• Kataoka T, Budd RC, Holler N, The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000;10:640-8
   PubMed Web of Science ®Google Scholar
• Merino D, Lalaoui N, Morizot A, Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006;26:7046-55
   PubMed Web of Science ®Google Scholar
• Horak P, Pils D, Haller G, Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 2005;3:335-43
   PubMed Web of Science ®Google Scholar
• Fisher MJ, Virmani AK, Wu L, Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001;7:1688-97
   PubMed Web of Science ®Google Scholar
• Bin L, Thorburn J, Thomas LR, Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem 2007;282:28189-94
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Kohlhaas SL, Sutcliffe MJ, TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005;65:11265-70
   PubMed Web of Science ®Google Scholar
• Wagner KW, Punnoose EA, Januario T, Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7
   PubMed Web of Science ®Google Scholar
• Pespeni MH, Hodnett M, Abayasiriwardana KS, Sensitization of mesothelioma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by heat stress via the inhibition of the 3-phosphoinositide-dependent kinase 1/Akt pathway. Cancer Res 2007;67:2865-71
   PubMed Web of Science ®Google Scholar
• Secchiero P, Gonelli A, Carnevale E, TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 2003;107:2250-6
   PubMed Web of Science ®Google Scholar
• Behbakht K, Qamar L, Aldridge CS, Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007;67:3036-42
   PubMed Web of Science ®Google Scholar
• Reichenberger KJ, Coletta RD, Schulte AP, Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Res 2005;65:2668-75
   PubMed Web of Science ®Google Scholar
• Imam JS, Buddavarapu K, Lee-Chang JS, MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 2010: published online 5 July 2010, doi: 10.1038/onc.2010.233
   Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8
   PubMed Web of Science ®Google Scholar
• Pitti RM, Marsters SA, Ruppert S, Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90
   PubMed Web of Science ®Google Scholar
• Schneider P. Production of recombinant TRAIL and TRAIL receptor: Fc chimeric proteins. Methods Enzymol 2000;322:325-45
   PubMed Web of Science ®Google Scholar
• Ganten TM, Koschny R, Sykora J, Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006;12:2640-6
   PubMed Web of Science ®Google Scholar
• Griffith TS, Broghammer EL. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001;4:257-66
   PubMed Web of Science ®Google Scholar
• Herman JR, Adler HL, Aguilar-Cordova E, In situ gene therapy for adenocarcinoma of the prostate: a Phase I clinical trial. Hum Gene Ther 1999;10:1239-49
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncol 2006;2:493-508
   PubMedGoogle Scholar
• Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004;4:333-9
   PubMed Web of Science ®Google Scholar
• Jo M, Kim TH, Seol DW, Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7
   PubMed Web of Science ®Google Scholar
• Lawrence D, Shahrokh Z, Marsters S, Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001;7:383-5
   PubMed Web of Science ®Google Scholar
• Mori E, Thomas M, Motoki K, Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 2004;11:203-7
   PubMed Web of Science ®Google Scholar
• Qin J, Chaturvedi V, Bonish B, Nickoloff BJ. Avoiding premature apoptosis of normal epidermal cells. Nat Med 2001;7:385-6
   PubMed Web of Science ®Google Scholar
• Takeda K, Kojima Y, Ikejima K, Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease. Proc Natl Acad Sci USA 2008;105:10895-900
   PubMed Web of Science ®Google Scholar
• Plummer R, Attard G, Pacey S, Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-94
   PubMed Web of Science ®Google Scholar
• Volkmann X, Fischer U, Bahr MJ, Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 2007;46:1498-508
   PubMed Web of Science ®Google Scholar
• Ozoren N, Kim K, Burns TF, The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res 2000;60:6259-65
   PubMed Web of Science ®Google Scholar
• Papenfuss K, Cordier SM, Walczak H. Death receptors as targets for anti-cancer therapy. J Cell Mol Med 2008;12:2566-85
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Mita M, Meropol NJ, Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5
   PubMed Web of Science ®Google Scholar
• Wakelee HA, Patnaik A, Sikic BI, Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2010;21:376-81
   Google Scholar
• Marini P, Denzinger S, Schiller D, Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-54
   PubMed Web of Science ®Google Scholar
• Natoni A, MacFarlane M, Inoue S, TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br J Haematol 2007;139:568-77
   PubMedGoogle Scholar
• Greco FA, Bonomi P, Crawford J, Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008;61:82-90
   PubMed Web of Science ®Google Scholar
• Trarbach T, Moehler M, Heinemann V, Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 2010;102:506-12
   PubMed Web of Science ®Google Scholar
• Mom CH, Verweij J, Oldenhuis CN, Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a Phase I study. Clin Cancer Res 2009;15:5584-90
   PubMed Web of Science ®Google Scholar
• Leong S, Cohen RB, Gustafson DL, Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a Phase I and pharmacokinetic study. J Clin Oncol 2009;27:4413-21
   PubMed Web of Science ®Google Scholar
• Abdulghani J, Mayes P, Dicker D, Sorafenib sensitizes hepatocellular carcinoma cells to TRAIL or TRAIL receptor agonist antibodies [abstract #833]. 99th AACR Annual Meeting; 12 – 16 April 2008; San Diego, CA
   Google Scholar
• Sikic BI, Wakelee HA, von Mehren M, Lewis N. A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25:18S [abstract 14006]
   Google Scholar
• Lu J, Sun H, McEachern D, In vivo tumor regression achieved by a potent bivalent Smac mimetic (SM-164) in combination with TRAIL [abstract C228]. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 22 – 26 October 2007; San Francisco, CA
   Google Scholar
• Buchsbaum DJ, Zhou T, Grizzle WE, Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003;9:3731-41
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Liu W, Zhao L, Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60
   PubMed Web of Science ®Google Scholar
• Saleh MN, Percent I, Wood TE, A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. 2008 ASCO Annual Meeting, J Clin Oncol 2008;26(20 Suppl): abstract 3537
   Google Scholar
• Li J, Knee DA, Wang Y, Zhang Q. LBY135, a novel anti-DR5 agonistic antibody induces tumor cell-specific cytotoxic activity in human colon tumor cell lines and xenografts. Drug Dev Res 2008;69:69-82
   Web of Science ®Google Scholar
• Sharma S, de Vries EG, Infante JR, Oldenhuis C. Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26(15S):3538
   Google Scholar
• Camidge D, Herbst RS, Gordon M, A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18S):3582
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98
   PubMed Web of Science ®Google Scholar
• Genentech BioOncology Pipeline Fact Sheet, Pipeline: Insight and Innovation from Genentech BioOncology. South San Francisco, CA, USA: Genentech, 2010. Available from: http://www.gene.com/gene/news/kits/biooncology/oncologypipeline.html [Last accessed 30 August 2010]
   Google Scholar
• LoRusso P, Hong D, Heath E, First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):3534
   PubMed Web of Science ®Google Scholar
• Yee L, Fanale M, Dimick K, Calvert S. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18S):8078
   Google Scholar
• Di Pietro R, Secchiero P, Rana R, Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) – mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 2001;97:2596-603
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Inoue S, Kohlhaas SL, Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005;12:773-82
   PubMed Web of Science ®Google Scholar
• Nakata S, Yoshida T, Horinaka M, Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004;23:6261-71
   PubMed Web of Science ®Google Scholar
• Yoshida T, Shiraishi T, Nakata S, Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res 2005;65:5662-7
   PubMed Web of Science ®Google Scholar
• He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004;23:2554-8
   PubMed Web of Science ®Google Scholar
• Voortman J, Resende TP, Abou El Hassan MA, TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007;6:2103-12
   PubMed Web of Science ®Google Scholar
• Gong B, Almasan A. Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res 2000;60:5754-60
   PubMed Web of Science ®Google Scholar
• Marini P, Schmid A, Jendrossek V, Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005;5:5
   PubMed Web of Science ®Google Scholar
• Tang X, Sun YJ, Half E, Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res 2002;62:4903-8
   PubMed Web of Science ®Google Scholar
• Liu X, Yue P, Zhou Z, Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004;96:1769-80
   PubMed Web of Science ®Google Scholar
• Huang Y, He Q, Hillman MJ, Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res 2001;61:6918-24
   PubMed Web of Science ®Google Scholar
• Kabore AF, Sun J, Hu X, The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 2006;11:1175-93
   PubMed Web of Science ®Google Scholar
• Fandy TE, Shankar S, Ross DD, Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005;7:646-57
   PubMed Web of Science ®Google Scholar
• Singh TR, Shankar S, Srivastava RK. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 2005;24:4609-23
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Penington RC. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol Cancer Ther 2005;4:1475-83
   PubMed Web of Science ®Google Scholar
• Evdokiou A, Bouralexis S, Atkins GJ, Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002;99:491-504
   PubMed Web of Science ®Google Scholar
• Wu XX, Kakehi Y, Mizutani Y, Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Int J Cancer 2003;104:409-17
   PubMed Web of Science ®Google Scholar
• Dolloff N, Mayes P, Dicker D, Novel target of lapatinib enhances anti-tumor activity via TRAIL sensitization [abstract # 835]. 99th AACR Annual Meeting; 12 – 16 April 2008; San Diego, CA
   Google Scholar